Related Experiment Video
Updated: Jun 17, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Drug-induced thrombocytopenia: pathogenesis, evaluation, and management
James N George1, Richard H Aster
1Department of Medicine, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA. james-george@ouhsc.edu
Hematology. American Society of Hematology. Education Program
|December 17, 2009
Summary
Drug-induced thrombocytopenia (DITP) is often unrecognized, but drug-dependent antibodies cause it. Promptly identifying and avoiding the causative drug is crucial for recovery from this platelet disorder.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Drug-induced thrombocytopenia (DITP) is a common immune-mediated condition in adults.
- The drug etiology behind DITP is frequently unrecognized.
- Most DITP cases involve drug-dependent antibodies binding to platelets in the drug's presence.
Purpose of the Study:
- To highlight the diagnostic challenges of DITP.
- To emphasize the importance of identifying causative drugs.
- To provide resources for understanding drug-platelet interactions.
Main Methods:
- Analysis of a comprehensive database of 1301 published reports.
- Inclusion of 317 distinct drugs linked to thrombocytopenia.
- Evaluation of the evidence for a causal relationship between drugs and thrombocytopenia.
Main Results:
- DITP typically manifests 1-2 weeks after initiating a new drug or suddenly after intermittent use.
- Severe, immediate thrombocytopenia can occur with antithrombotic agents targeting platelet GP IIb-IIIa.
- Recovery usually occurs within 1-7 days of drug cessation.
Conclusions:
- Confirming drug etiology is vital for managing DITP.
- Avoiding the implicated drug is essential for long-term patient safety.
- Drug-dependent antibodies can persist long-term, necessitating continued drug avoidance.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...